Corcept Therapeutics

Avidity Biosciences

Krystal Biotech

Arcellx

Alkermes

Crinetics Pharmaceuticals Inc

Immunovant Inc

Denali Therapeutics

Merus

Xenon Pharmaceuticals

ALPS Medical Breakthroughs ETF

SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.

Road Town, Virgin Islands--(Newsfile Corp. - September 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Vector Space Biosciences (SBIO) on September 15, 2023. For all users of LBank Exchange, the SBIO/USDT trading pair is now officially available for trading.

Vector Space Biosciences (SBIO) Is Now Available for Trading on LBank Exchange

Defiance Hotel Airline and Cruise ETF

VanEck Vectors Digital Transformation ETF

iShares U.S. Home Construction ETF

Consumer Discretionary Select Sector SPDR Fund

Wall Street is on track to end the second quarter on a positive note. The Nasdaq Composite Index has outperformed, gaining 10.9% since the start of April, while the S&P 500 and the Dow Jones are up 6.6% and 2%, respectively.

5 Top-Performing Sector ETFs of Q2

ARK Innovation ETF

ALPS Barron's 400 ETF

With news that inflation once again cooled arriving on Tuesday, investors may be feeling more confident about a Fed rate pause. Markets have been excited by the prospect of a pause in ongoing rates for months.

3 Growth-Minded ETFs to Play Fed Rate Pause

Roundhill Sports Betting & iGaming ETF

U.S. Global GO GOLD and Precious Metal Miners ETF

Wall Street wrapped up a winning April buoyed by better-than-expected earnings and easing of banking fears. Cooling inflation added to the strength.

5 Sector ETFs That Beat the Market in April

Teucrium Sugar Fund

iPath Series B Bloomberg Platinum Subindex Total Return ETN

Aberdeen Standard Physical Platinum Shares ETF

iPath Series B Bloomberg Sugar Subindex Total Return ETN

Valkyrie Bitcoin Miners ETF

April brings with it seasonal tailwinds for the equity world. Digital Assets, Sugar, Platinum, Biotech and Homebuilding were clear winners in the month.

5 Best ETF Areas of April Up At Least 10%

Virtus LifeSci Biotech Clinical Trials ETF

Loncar Cancer Immunotherapy ETF

Global X MSCI Nigeria ETF

Aberdeen Standard Physical Palladium Shares ETF 

GraniteShares Platinum Trust

Invesco DWA Healthcare Momentum ETF

Simplify Propel Opportunities ETF

In a somewhat surprising turn, biotech and life sciences-focused ETFs were the driving themes in the last week's top-performing ETFs, with the ALPS Medical Breakthroughs ETF (SBIO) leading the way with a 10% return.

ALPS' Biotech ETF SBIO Week's Top Performer

ARK Genomic Revolution Multi-Sector ETF

SPDR S&P Biotech ETF

Biotech comes with a great many positive externalities for society, and can be a big positive for portfolios right now.

Biotech ETFs' Performance Deserves A Look

Global X Genomics & Biotechnology ETF

iShares Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector

One of the long-running catalysts for small- and mid-sized biotechnology companies is the possibility that they'll eventually be acquired by large-cap brethren or blue-chip pharmaceutical firms. While the biotech industry's history of mergers and acquisitions is extensive, deal-making in the space has been sluggish over the past couple of years, frustrating investors in the process.

Biotech M&A Could Finally Be Ready to Rebound

Global X Longevity Thematic ETF 

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

BlackRock Future Health ETF

Principal Healthcare Innovators Index ETF

Global X Telemedicine & Digital Health ETF

First Trust NYSE Arca Biotechnology Index Fund

Fidelity MSCI Health Care ETF

First Trust Nasdaq Pharmaceuticals ETF 

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

 Franklin Genomic Advancements ETF

ROBO Global Healthcare Technology and Innovation ETF

Invesco Nasdaq Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare Providers ETF

iShares U.S. Medical Devices ETF

iShares Global Healthcare ETF

iShares U.S. Healthcare ETF

Eli Lilly

Global X Longevity Thematic ETF

First Trust Indxx Medical Devices ETF

Merck

Novo Nordisk

Invesco Dynamic Biotechnology & Genome ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Simplify Health Care ETF

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

Invesco S&P SmallCap Health Care ETF

Invesco S&P 500 Equal Weight Health Care ETF

Vanguard Health Care ETF

Wisdomtree BioRevolution Fund

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Can Health Care Stocks Outperform Again In 2023?

ETFs offering biotech exposure are rallying on Monday, lifted by a significant M&A announcement in the industry. The ALPS Medical Breakthroughs ETF (SBIO) increased by 1.8% in mid-day trading on Monday.

Look to SBIO for Biotech Exposure

With technology ETFs taking in $3.2 billion over one month, compared to overall -$4 billion in YTD outflows according to YCharts, investors are looking for the right tech subsector in which to invest.

Gene Deal Adds New Dimension to Biotech ETF SBIO

The ALPS Medical Breakthroughs ETF (SBIO) rallied 3.66% last week, outpacing competing biotech ETFs and major U.S. indexes. The biotech sector was propelled last week by long-awaited breakthrough Alzheimer's trial data.

SBIO Rallied While Major Indexes Declined Last Week

Despite last week's volatility, positive sentiment throughout the biotech industry continued to intensify, propelled by favorable legislation and encouraging trial data.

SBIO Outpaced XBI, IBB in Volatile Last Week

The ALPS Medical Breakthroughs ETF (SBIO) was ALPS' top-performing ETF in August, propelled by positive earnings and M&A announcements in the portfolio.   SBIO increased 8.65% on a total return basis between August 1 and August 31.

SBIO Was ALPS' Top Performing ETF in August

Biotechnology sector-related exchange traded funds retreated with Novavax Inc. (NasdaqGS: NVAX), plunging after the vaccine developer cut its 2022 revenue guidance in half. On Tuesday, the iShares Genomics Immunology and Healthcare ETF (IDNA) fell 4.1%, ETFMG Treatments Testing and Advancements ETF (GERM) dropped 4.3%, SPDR S&P Biotech ETF (XBI) decreased 3.

Biotech ETFs Slip After Novavax Cuts 2022 Guidance

ARK Fintech Innovation ETF

First Trust SkyBridge Crypto Industry and Digital Economy ETF

Fidelity Covington Trust-Fidelity Crypto Industry And Digital Payments Etf

Direxion mRNA ETF

Biotech and cryptocurrency -- two ETF areas outperformed last week.

Biotech & Crypto -- Best ETF Areas of Last Week

Pfizer

The biotech corner of the broad healthcare sector outperformed last week on speculation over a takeover bid for Global Blood Therapeutics.

Biotech Wins Last Week: 5 Best ETFs

Biotechnology sector-related exchange traded funds continued to rally Friday on reports that Pfizer Inc. (NYSE: PFE) is looking to acquire Global Blood Therapeutics (NasdaqGS: GBT). On Friday, the Virtus LifeSci Biotech Products ETF (BBP) rose 1.8%, the SPDR S&P Biotech ETF (XBI) increased 3.6%, and the ALPS Medical Breakthroughs ETF (SBIO) was up 3.9%.

Biotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal

Global Blood Therapeutics (NasdaqGS: GBT) shares climbed Thursday, lifting biotechnology sector-related exchange traded funds, on speculation of takeover bids for the small drug developer. On Thursday, the Virtus LifeSci Biotech Products ETF (BBP) rose 7.2%, the SPDR S&P Biotech ETF (XBI) increased 5.2%, and the ALPS Medical Breakthroughs ETF (SBIO) was up 5.1%.

Biotech ETFs Advance on Speculation of a Takeover Bid for Global Blood Therapeutics

A surge in biotech stocks that began in mid-June is lasting longer than skeptics expected, with no signs of slowing down. The ALPS Medical Breakthroughs ETF (SBIO) gained 7.74% in June as positive drug trial data and M&A activity in the biotech space outweighed investors' broad market recession fears.

SBIO Increases on Biotech's Sustained Rebound

Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.

5 ETFs Riding High on the Biotech Comeback

Biotechnology stocks and sector-related exchange traded funds have been gaining momentum as investors return to this downtrodden segment of the market. Over the past month, the Virtus LifeSci Biotech Clinical Trials ETF (BBC) gained 15.5%, the Virtus LifeSci Biotech Products ETF (BBP) rose 12.8%, the SPDR S&P Biotech ETF (XBI) increased 11.3% and the ALPS [.

Biotech ETFs Are Making a Comeback

The ALPS Medical Breakthroughs ETF (SBIO) rallied 11.53% last week on positive trial data and merger and acquisition news that revived the biotech sector.  The small- and mid-cap biotech companies among SBIO's holdings outperformed large-cap biotech indexes by nearly 200 bps last week on positive drug trial data for companies focused on immunotherapy, with their [.

SBIO Continues Rally on Breakthrough Drug Data

Biotechnology stocks and the related exchange traded funds are under pressure as growth stocks stumble this year, but interested investors have some potential positive facts to ponder. First, biotech valuations are at depressed, rarely seen levels.

News for ALPS Medical Breakthroughs ETF ETF (SBIO)